Paratek Pharmaceuticals, Inc. PRTK
Set alert
At close · Sep 20
52-week range unavailable
- Open
- 2.19
- Prev close
- 2.23
- Mkt cap
- 126.02M
- Vol
- 4.48M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.19
- High
- 2.24
- Forward P/E
- -27.50
- Beta
- 1.71
- Short ratio
- 1.47
- Inst. own
- 52.56%
- Dividend
- 0.00
- Ex-div date
- Oct 30, 2014
- Earnings
- Nov 2, 2023
- 50-d avg
- 1.98
- 200-d avg
- 2.19
- 1y target
- 3.10
6M chart
Events in this range
- May 9, 2023Earnings: —; estimate -0.38; surprise —%
- Jun 7, 2023Downgrade: Jefferies · Buy → Hold
- Jun 7, 2023Downgrade: HC Wainwright & Co. · Buy → Neutral
- Jul 10, 2023Rating: HC Wainwright & Co. · Neutral → Neutral
- Aug 3, 2023Earnings: —; estimate -0.31; surprise —%
Signals (22)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Sep 21, 2023 | 3 years ago |
| SMA: Bullish | Sep 20, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 13, 2023 | 3 years ago |
| SMA: Bullish | Sep 5, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 5, 2023 | 3 years ago |
| SMA: Bearish | Sep 1, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 1, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 30, 2023 | 3 years ago |
| SMA: Bullish | Aug 24, 2023 | 3 years ago |
| SMA: Bearish | Aug 21, 2023 | 3 years ago |
| SMA: Bullish | Aug 18, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 29, 2023 | 3 years ago |
| SMA: Bullish | Jun 6, 2023 | 3 years ago |
| SMA: Bullish | Jun 6, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 2, 2023 | 3 years ago |
| MACD: Sell Signal | May 26, 2023 | 3 years ago |
| MACD: Buy Signal | May 11, 2023 | 3 years ago |
| SMA: Bearish | Apr 24, 2023 | 3 years ago |
| SMA: Bearish | Apr 24, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 19, 2023 | 3 years ago |
| RSI: Overbought | Apr 3, 2023 | 3 years ago |
| SMA: Bullish | Mar 30, 2023 | 3 years ago |
Key statistics
- Market cap
- 126.02M
- Enterprise value
- 340.56M
- Trailing P/E
- 0.00
- Forward P/E
- -27.50
- PEG ratio
- 0.02
- Price / sales
- 0.76
- Price / book
- 0.00
- EPS (TTM)
- -1.18
- Beta
- 1.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -39.49%
- Revenue (TTM)
- 166.64M
- Revenue growth
- 25.60%
- Free cash flow
- -36.90M
- Total cash
- 45.03M
- Total debt
- 259.57M
- Return on equity
- 0.00%
- Shares outstanding
- 57.28M
- Short % of float
- 5.39%
- 50-day average
- 1.98
- 200-day average
- 2.19
Analyst view
Consensus: buy
- Target (low)
- 2.15
- Target (mean)
- 3.10
- Target (high)
- 5.00
- Strong buy7
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 2, 2023
Expected Nov 2, 2023. Consensus EPS estimate -0.31.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2023 | Sep 1, 2023 | -0.25 | — | — | — |
| Aug 3, 2023 | Jun 1, 2023 | -0.31 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | -0.38 | — | — | — |
| Mar 16, 2023 | Dec 1, 2022 | 0.01 | — | — | — |
| Nov 3, 2022 | Sep 1, 2022 | -0.27 | — | — | — |
| Aug 3, 2022 | Jun 1, 2022 | -0.35 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 10, 2023 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Jun 7, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 7, 2023 | Jefferies | down | Buy | Hold |
| Mar 20, 2023 | HC Wainwright & Co. | main | — | Buy |
| May 6, 2022 | HC Wainwright & Co. | main | — | Buy |
| Mar 17, 2022 | HC Wainwright & Co. | main | — | Buy |
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- paratekpharma.com
News
- Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026
- Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform
- Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract
- Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025
- Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference
- Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
- Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities
- Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease
- Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
- Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
Your note
Sign in to keep a note on PRTK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAYLOR-HENRY MINNIE | Director | Stock Award(Grant) | Feb 7, 2023 | 59,200 |
| BIGHAM MICHAEL F | Officer and Director | Sale | Dec 20, 2022 | 1,209,700 |
| DIETZ THOMAS JOHN | Director | Stock Award(Grant) | Feb 7, 2023 | 70,000 |
| DONDERO JAMES DAVID | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 22, 2023 | 0 |
| FRANSON TIMOTHY R | Director | Sale | Feb 20, 2023 | 72,000 |
| HASKEL WILLIAM M | General Counsel | Sale | Dec 20, 2022 | 407,800 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIGH Capital Management LLC | 4.67% | 2,674,812 | 5.88M | Mar 30, 2023 |
| Nexpoint Asset Management, L.P. | 4.36% | 2,495,770 | 5.49M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 3.89% | 2,228,066 | 4.90M | Mar 30, 2023 |
| Omega Fund Management, Llc | 3.44% | 1,971,241 | 4.34M | Mar 30, 2023 |
| General American Investors Company Inc | 3.34% | 1,914,424 | 4.21M | Mar 30, 2023 |
| Rock Springs Capital Management, LP | 3.03% | 1,734,037 | 3.81M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| General American Investors Co | 3.29% | 1,884,393 | 4.15M | Dec 30, 2022 |
| Vanguard Total Stock Market Index Fund | 2.52% | 1,443,552 | 3.18M | Dec 30, 2022 |
| Bruce & Co., Inc. | 2.49% | 1,427,412 | 3.14M | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 1.18% | 676,071 | 1.49M | Dec 30, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.71% | 408,008 | 897.62K | Feb 27, 2023 |
| Fidelity Extended Market Index Fund | 0.43% | 246,091 | 541.40K | Feb 27, 2023 |